Balance Sheet
Cash Flow Statement
Beginning Cash BalanceGains from Sales and Divestitures
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Share-based Compensation: 2012-2022

Historic Share-based Compensation for RedHill Biopharma (RDHL) over the last 11 years, with Dec 2022 value amounting to $1.1 million.

  • RedHill Biopharma's Share-based Compensation fell 39.36% to $1.1 million in Q4 2022 from the same period last year, while for Dec 2022 it was $5.7 million, marking a year-over-year decrease of 44.43%. This contributed to the annual value of $665,000 for FY2024, which is 59.62% down from last year.
  • As of Q4 2022, RedHill Biopharma's Share-based Compensation stood at $1.1 million, which was down 29.55% from $1.6 million recorded in Q3 2022.
  • RedHill Biopharma's Share-based Compensation's 5-year high stood at $5.3 million during Q2 2021, with a 5-year trough of $468,000 in Q3 2018.
  • For the 3-year period, RedHill Biopharma's Share-based Compensation averaged around $1.7 million, with its median value being $1.4 million (2022).
  • Per our database at Business Quant, RedHill Biopharma's Share-based Compensation skyrocketed by 746.55% in 2021 and then tumbled by 88.28% in 2022.
  • Quarterly analysis of 5 years shows RedHill Biopharma's Share-based Compensation stood at $671,000 in 2018, then increased by 11.62% to $749,000 in 2019, then skyrocketed by 44.46% to $1.1 million in 2020, then spiked by 73.29% to $1.9 million in 2021, then slumped by 39.36% to $1.1 million in 2022.
  • Its Share-based Compensation stands at $1.1 million for Q4 2022, versus $1.6 million for Q3 2022 and $618,000 for Q2 2022.